<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981721</url>
  </required_header>
  <id_info>
    <org_study_id>D8480C00060</org_study_id>
    <nct_id>NCT00981721</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies</brief_title>
  <official_title>A Phase I, Randomised, Multi-centre, Open-label Study to Determine the Pharmacokinetics and Tolerability of Cediranib (RECENTIN™, AZD2171) Following a Single and Multiple Oral 20mg or 30 mg Doses in Chinese Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being carried out to see how single and multiple doses of cediranib are handled
      by the body (that is how they are absorbed, broken down and got rid of from the body) by
      measuring levels of drug in the blood in Chinese patients with advanced solid malignancies.

      The study will also assess the tolerability of 20 or 30 mg cediranib in Chinese patients and
      how the tumour responds to treatment with cediranib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the pharmacokinetics of single dose of cediranib 20mg or 30 mg by assessment of area under the curve over the time (AUC) and maximum concentration in Chinese patients with advanced solid malignant tumours</measure>
    <time_frame>Multiple assessments in the first 6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetics of multiple doses of cediranib 20mg or 30 mg in Chinese patients with advanced solid malignant tumours</measure>
    <time_frame>Multiple assessments up to day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of single and multiple doses of cediranib 20mg or 30 mg in Chinese patients with advanced solid malignancies.</measure>
    <time_frame>Safety assessments to be taken until Day 29 (while patient remains on study treatment), then every 4 weeks until treatment discontinuation and then 30 day follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cediranib 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cediranib 30mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cediranib (RECENTIN TM, AZD2171)</intervention_name>
    <description>20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent

          -  Histological and/or cytological confirmed advanced solid malignancies

          -  Refractory to conventional therapeutic modalities, or for which no appropriate
             therapies exist

        Exclusion Criteria:

          -  For the first question: Patients with a history of poorly controlled hypertension with
             resting blood pressure &gt;150/100 mmHg in the presence or absence of a stable regimen of
             antihypertensive therapy, or patients who are requiring maximal doses of calcium
             channel blockers to stabilize blood pressure.

          -  Significant haemorrhage (&gt;30 ml/bleeding episode in previous 3 months), haemoptysis
             (&gt;5 ml fresh blood in previous 4 weeks) or thrombotic event (including transient
             ischaemic attack) in the previous 12 months

          -  Recent(&lt;28 days) major thoracic and abdominal surgery prior to entry into the study,
             or a surgical incision that is not fully healed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeannie Hou</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca China MC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sun Yan, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital, CAMS&amp;PUMC, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>June 17, 2011</last_update_submitted>
  <last_update_submitted_qc>June 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Advanced solid malignancies</keyword>
  <keyword>Advanced solid tumour</keyword>
  <keyword>Advanced cancer</keyword>
  <keyword>Cediranib (RECENTIN™, AZD2171)</keyword>
  <keyword>China</keyword>
  <keyword>PK</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

